Your browser is no longer supported. Please, upgrade your browser.
Settings
MNK Mallinckrodt plc daily Stock Chart
MNK [NYSE]
Mallinckrodt plc
Index- P/E- EPS (ttm)-14.48 Insider Own0.90% Shs Outstand84.20M Perf Week-16.72%
Market Cap241.50M Forward P/E0.68 EPS next Y4.11 Insider Trans0.00% Shs Float83.10M Perf Month-16.22%
Income-1219.10M PEG- EPS next Q1.36 Inst Own81.70% Short Float55.27% Perf Quarter-10.86%
Sales3.04B P/S0.08 EPS this Y72.20% Inst Trans-12.15% Short Ratio6.82 Perf Half Y-25.99%
Book/sh22.52 P/B0.12 EPS next Y-33.66% ROA-11.70% Target Price3.13 Perf Year-69.21%
Cash/sh9.33 P/C0.30 EPS next 5Y-11.70% ROE-48.10% 52W Range1.00 - 10.54 Perf YTD-20.06%
Dividend- P/FCF0.47 EPS past 5Y-51.60% ROI-10.50% 52W High-73.15% Beta3.44
Dividend %- Quick Ratio1.20 Sales past 5Y1.60% Gross Margin45.10% 52W Low183.00% ATR0.30
Employees3400 Current Ratio1.50 Sales Q/Q-15.80% Oper. Margin-45.30% RSI (14)47.45 Volatility9.20% 9.31%
OptionableYes Debt/Eq2.83 EPS Q/Q-136.70% Profit Margin-39.60% Rel Volume0.41 Prev Close2.79
ShortableYes LT Debt/Eq2.50 EarningsMay 05 BMO Payout- Avg Volume6.73M Price2.83
Recom3.20 SMA20-7.91% SMA50-4.97% SMA200-14.78% Volume263,113 Change1.43%
May-19-20Downgrade JP Morgan Neutral → Underweight
Sep-05-19Reiterated BofA/Merrill Underperform $5 → $1
Sep-05-19Downgrade BMO Capital Markets Outperform → Market Perform
Sep-03-19Reiterated Berenberg Sell $5 → $1
Jun-11-19Initiated Barclays Equal Weight
May-31-19Downgrade Piper Jaffray Overweight → Neutral
May-22-19Downgrade Jefferies Buy → Hold
Mar-20-19Initiated SunTrust Hold
Nov-19-18Upgrade Canaccord Genuity Hold → Buy $34 → $40
Sep-11-18Downgrade Goldman Neutral → Sell
Aug-24-18Reiterated B. Riley FBR Neutral $20 → $37
Aug-08-18Reiterated Stifel Hold $18 → $30
Aug-08-18Downgrade Raymond James Outperform → Mkt Perform
May-09-18Reiterated Barclays Underweight $20 → $12
May-02-18Initiated B. Riley FBR, Inc. Neutral $15
Mar-09-18Reiterated Mizuho Neutral $21 → $16
Feb-02-18Downgrade Barclays Equal Weight → Underweight $23 → $20
Jan-09-18Reiterated Mizuho Neutral $22 → $21
Jan-03-18Initiated Leerink Partners Mkt Perform $26
Nov-08-17Reiterated Canaccord Genuity Buy $38 → $24
Jun-01-20 08:35AM  
06:45AM  
May-31-20 06:35AM  
May-15-20 06:23AM  
May-06-20 11:34AM  
08:29AM  
May-05-20 10:01PM  
04:49PM  
09:55AM  
07:11AM  
06:45AM  
May-04-20 06:45AM  
Apr-30-20 08:04AM  
Apr-28-20 12:33PM  
Apr-22-20 06:45AM  
Apr-21-20 12:19PM  
Apr-16-20 06:45AM  
Apr-15-20 08:03AM  
06:45AM  
Apr-08-20 12:10PM  
Apr-07-20 11:14AM  
10:22AM  
09:46AM  
08:48AM  
Apr-06-20 06:45AM  
Apr-01-20 06:45AM  
06:45AM  
Mar-19-20 10:03AM  
Mar-18-20 08:50AM  
Mar-17-20 08:48AM  
06:45AM  
Mar-16-20 02:51PM  
06:18AM  
06:00AM  
Mar-13-20 11:01AM  
Mar-12-20 09:35AM  
07:37AM  
06:45AM  
Mar-11-20 08:03AM  
06:00AM  
04:18AM  
Mar-06-20 03:26PM  
08:35AM  
Mar-05-20 06:45AM  
Mar-04-20 07:37AM  
06:45AM  
Mar-03-20 02:26PM  
12:16PM  
Mar-02-20 06:45AM  
Feb-27-20 06:45AM  
01:18AM  
Feb-26-20 02:49PM  
01:18PM  
05:48AM  
05:00AM  
Feb-25-20 04:27PM  
11:14AM  
10:03AM  
08:56AM  
08:28AM  
08:23AM  
08:19AM  
08:05AM  
07:44AM  
07:30AM  
07:23AM  
06:37AM  
06:30AM  
06:05AM  
06:00AM  
Feb-24-20 03:40PM  
02:48PM  
02:46PM  
10:12AM  
Feb-14-20 07:38AM  
Feb-10-20 02:43PM  
Feb-06-20 03:34PM  
12:10PM  
11:17AM  
08:40AM  
Jan-22-20 02:48PM  
Jan-20-20 09:30AM  
08:17AM  
Jan-15-20 01:55PM  
Jan-13-20 09:11AM  
Dec-30-19 09:12AM  
Dec-23-19 06:45AM  
Dec-19-19 06:00AM  
Dec-17-19 10:25AM  
Dec-16-19 04:45PM  
Dec-11-19 08:52AM  
Dec-10-19 12:49PM  
06:45AM  
Dec-09-19 10:04AM  
Dec-07-19 12:05PM  
Dec-06-19 11:33AM  
Dec-05-19 11:31AM  
06:45AM  
Dec-04-19 07:59AM  
Dec-02-19 07:20PM  
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform, as well as Amitiza, a product for constipation. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reasons Bryan M.EVP & CFOJun 07Buy8.965,40048,38317,979Jun 07 04:12 PM